OSE Immunotherapeutics Stock
Stocks
OSE
FR0012127173
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Euronext Paris
19:55:00 03/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 3.070 EUR | -4.42% |
|
-4.54% | -40.39% |
| 09-02 | OSE Immunotherapeutics SA - Special Call | |
| 08-19 | Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine | RE |
| Market Cap | 72.21M 83.94M 67.75M 62.04M 116M 7.94B 117M 801M 312M 4.06B 315M 308M 13.08B | P/E 2026 * |
-2.36x | P/E 2027 * | -2.7x |
|---|---|---|---|---|---|
| Enterprise Value | 113M 131M 106M 97.09M 181M 12.43B 182M 1.25B 488M 6.35B 493M 482M 20.47B | EV / Sales 2026 * |
23.1x | EV / Sales 2027 * | 12.8x |
| Free-Float |
78.15% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| OSE | Real-time | |
CBOE
| OSEp | Real-time | |
|
Tradegate
| 6OP | Real-time | |
|
Börse Stuttgart
| 6OP | Delayed | |
|
Boerse Muenchen
| 6OP | Real-time | |
|
Deutsche Boerse AG
| 6OP | Delayed | |
|
CBOE
| 0RAD | Real-time |
Last Transcript : OSE Immunotherapeutics
| 1 day | -4.42% | ||
| 1 week | -4.54% | ||
| Current month | -4.54% | ||
| 1 month | -4.24% | ||
| 3 months | -19.68% | ||
| 6 months | -27.76% | ||
| Current year | -40.39% |
| 1 week | 3.06 |  | 3.32 |
| 1 month | 3.06 | | 3.54 |
| Current year | 2.87 | | 5.9 |
| 1 year | 2.87 | | 7.7 |
| 3 years | 2.87 | | 11.58 |
| 5 years | 2.7 | | 13.68 |
| 10 years | 2.7 | | 15.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Bozec
CEO | Chief Executive Officer | - | 02/10/2025 |
Thomas Gidoin
DFI | Director of Finance/CFO | 43 | 20/08/2025 |
Silvia Comis
CTO | Chief Tech/Sci/R&D Officer | - | 20/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Maryvonne Hiance
BRD | Director/Board Member | 77 | 31/05/2016 |
Brigitte Dreno
BRD | Director/Board Member | 73 | 14/06/2017 |
| Director/Board Member | - | 22/06/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 13/11/24 | Sell | Director | 30,000 | 0.1375% | ||
| 12/11/24 | Sell | Chief Administrative Officer | 10,000 | 0.0458% | ||
| 21/06/24 | Exercice | Director | 10,000 | 0.0459% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.42% | -4.54% | -50.36% | -5.54% | 87.57M | |
| -0.24% | -0.99% | +3.26% | +18.17% | 50.14B | |
| +0.78% | -2.12% | +433.44% | +501.63% | 44.85B | |
| +2.95% | +3.87% | +47.83% | +21.08% | 43.43B | |
| +0.25% | -3.49% | +9.23% | +73.60% | 41.14B | |
| +0.43% | -3.26% | +14.75% | +49.08% | 32.92B | |
| +1.43% | +8.34% | - | - | 17.56B | |
| +0.06% | -4.15% | +25.36% | +116.96% | 16.55B | |
| +0.93% | +0.88% | +19.64% | +29.70% | 14.65B | |
| +0.54% | -0.59% | +81.92% | +39.94% | 13.93B | |
| Average | +0.27% | -0.70% | +65.01% | +93.85% | 27.52B | |
| Weighted average by Cap. | +0.81% | -1.13% | +94.64% | +123.77% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.9M 5.7M 4.6M 4.21M 7.86M 539M 7.91M 54.34M 21.16M 275M 21.39M 20.92M 888M | 10.53M 12.24M 9.88M 9.05M 16.88M 1.16B 17M 117M 45.48M 592M 45.96M 44.96M 1.91B |
| Net income | -30.59M -35.56M -28.7M -26.28M -49.04M -3.36B -49.37M -339M -132M -1.72B -133M -131M -5.54B | -21.47M -24.96M -20.14M -18.45M -34.42M -2.36B -34.65M -238M -92.72M -1.21B -93.7M -91.66M -3.89B |
| Net Debt | 40.79M 47.42M 38.27M 35.05M 65.4M 4.49B 65.84M 452M 176M 2.29B 178M 174M 7.39B | 63.08M 73.34M 59.19M 54.21M 101M 6.94B 102M 700M 272M 3.55B 275M 269M 11.43B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/09/26 | €3.070 | -4.42% | 196,258 |
| 02/09/26 | €3.212 | +0.50% | 117,228 |
| 01/09/26 | €3.196 | -0.62% | 69,800 |
| 31/08/26 | €3.216 | +0.82% | 57,350 |
| 28/08/26 | €3.190 | -1.05% | 107,049 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- OSE Stock
Select your edition
All financial news and data tailored to specific country editions
